Should America Replace Private Insurance With Medicare for All?
The US spends twice the OECD per-capita average yet ranks last among wealthy nations in health outcomes. 32 million Americans have no coverage. Should one public payer replace private insurance entirely? Two debaters, opposing sides — you score who makes the stronger case.
Wednesday, September 2, 2026 · 7:00 PM EDT
What's at stake
If M4A works, 32 million Americans gain coverage and medical bankruptcies end. If it fails, a $30 trillion gamble dismantles a system 160 million people currently rely on.
The Matchup
The Positions
Every wealthy country with universal healthcare spends less than the US and achieves better outcomes. Private insurance is the inefficiency — not the solution.
- The US spent $4.5 trillion on healthcare in 2022 — more than $13,000 per person — yet 32 million remained uninsured. Administrative overhead alone consumes 34 cents of every private-insurance dollar; Canada's single-payer spends 12 cents. M4A's administrative savings alone could cover the uninsured.
- Medical debt triggers more than 60% of personal bankruptcies in the United States. This happens in no other wealthy country. A system that ties coverage to employment forces workers to stay in jobs they would otherwise leave — suppressing wages, innovation, and entrepreneurship.
- The VA, Medicare, and Medicaid already demonstrate that government can administer large health programs. Medicare has a 2% administrative cost vs. 12% for private insurers. The infrastructure for a single-payer transition already exists at scale.
Debater: To be announced
Medicare for All would cost $30+ trillion over a decade, require the largest tax increase in US history, and give government bureaucrats control over the medical decisions of 330 million people.
- Independent analyses estimate M4A at $30–40 trillion in new federal spending over ten years. Financing it requires roughly doubling federal income taxes or equivalent revenue — a political and economic constraint that no serious M4A proposal has resolved without painful tradeoffs.
- The US produces 40% of the world's new drugs and medical devices, driven by the profit incentives of a competitive market. Single-payer systems in Europe and Canada routinely delay access to cutting-edge treatments that US patients get first. Eliminating private insurance removes the pricing signal that drives pharmaceutical R&D.
- 2 million Americans work in private health insurance. M4A would eliminate most of those jobs over a 4-year transition. While Medicare would expand, the net displacement of skilled workers in a short window would ripple through the economy — a human cost M4A advocates routinely undercount.
Debater: To be announced
Join the debate
Make your case
Record a 60-second video on either side, or make it in writing. The strongest cases get featured before the live debate.
“I'm British and have lived in the US for 36 years, so I feel qualified to present the facts. No one in the UK has to worry about a medical bill or going to see a doctor. What no one tells you here in the US is that you can buy private insurance in the UK. It's not all or nothing. You pay into the system just like you pay into social security. I will retire back to the UK, as the last thing I want to worry about is medical bills. The system in the UK is not perfect. 99% of the people that are against single payer healthcare have never lived anywhere outside the US.”
“The US spent $4.5 trillion on healthcare in 2022 — more than $13,000 per person — yet 32 million remained uninsured. Administrative overhead alone consumes 34 cents of every private-insurance dollar; Canada's single-payer spends 12 cents. M4A's administrative savings alone could cover the uninsured.”
“Independent analyses estimate M4A at $30–40 trillion in new federal spending over ten years. Financing it requires roughly doubling federal income taxes or equivalent revenue — a political and economic constraint that no serious M4A proposal has resolved without painful tradeoffs.”
“The US produces 40% of the world's new drugs and medical devices, driven by the profit incentives of a competitive market. Single-payer systems in Europe and Canada routinely delay access to cutting-edge treatments that US patients get first. Eliminating private insurance removes the pricing signal that drives pharmaceutical R&D.”
The Format
The run of show
Standard SuperDebate: two people, cross-examination, moderated from start to finish.
- 01
Opening Argument
4 min · PRO · opening case
- 02
Cross-Examination
4 min · CON questions PRO
- 03
Opening Argument
4 min · CON · opening case
- 04
Cross-Examination
4 min · PRO questions CON
- 05
Rebuttal
3 min · PRO
- 06
Rebuttal
3 min · CON
- 07
Closing Statement
3 min · PRO · final case
- 08
Closing Statement
3 min · CON · final case
- 09
Audience Vote
— · You pick the winner
Don't miss it
Stay in the loop
The debate happens live with real-time audience voting. Get one email right before we go live, with the watch link.
Premieres
Wednesday, September 2, 2026 · 7:00 PM EDT
Get Involved
Open debate runs on the people who show up. Tell us how you want to be part of it.
More Debates
Structured debates on the ideas that matter most. You score who makes the stronger case.
